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Introduction {#sec001}
============

In this study, we sought to clarify the mechanism of neurally mediated syncope (NMS). In recent years, approximately 20% of unknown syncope cases were considered to be NMS \[[@pone.0214733.ref001]--[@pone.0214733.ref003]\]. Frequently occurring NMS lead to problems in everyday life \[[@pone.0214733.ref004], [@pone.0214733.ref005]\]. The underlying mechanisms causing NMS have yet to be clarified before any treatment can be proposed to patients.

In general, NMS patients are treated lightly as they quickly recover consciousness. However, while NMS itself is not fatal, NMS patients can experience secondary damage (head or chest contusion etc.) as a result of collapse \[[@pone.0214733.ref006]--[@pone.0214733.ref009]\]. Moreover, when the individual affected by NMS are drivers, this can lead to dangerous situations involving other people \[[@pone.0214733.ref006], [@pone.0214733.ref010], [@pone.0214733.ref011]\]. Regarding the impact on the patient and his environment, NMS needs to be considered a serious disease, its causes clarified, and proper diagnosis methods developed. In the NMS diagnosis, understanding the cause of symptoms is very important, such as for instance fainting in a standing or sitting position. However, since many diseases can result in fainting spells (e.g., orthostatic hypotension, cardiogenic syncope, arrhythmia, epilepsy, and cerebral vascular disorders), various additional examinations are required to confirm syncope-related symptoms \[[@pone.0214733.ref012]--[@pone.0214733.ref018]\]. If NMS is suspected, diagnosis will entail conducting a head-up tilt (HUT) test \[[@pone.0214733.ref019]--[@pone.0214733.ref022]\]. The HUT test will classify the NMS into one of the three different types: the vasodepressor type (VT), mixed type (MT), and cardioinhibitory type (CT) \[[@pone.0214733.ref023]--[@pone.0214733.ref027]\].

AC mediates the effects of the Gi protein on the contraction and relaxation of blood vessels by acting on α2B-AR \[[@pone.0214733.ref028]--[@pone.0214733.ref038]\]. When activated, the β2 receptor promotes the binding of AC to the Gs protein to generate cAMP \[[@pone.0214733.ref039]--[@pone.0214733.ref043]\]. When cAMP activates protein kinase A, calcium ion channels are opened, accelerating calcium uptake by the sarcoplasmic reticulum \[[@pone.0214733.ref040], [@pone.0214733.ref044]--[@pone.0214733.ref046]\]. Consequently, increased calcium concentrations lead to an increase in the contractile force of smooth muscle \[[@pone.0214733.ref047]--[@pone.0214733.ref050]\]. Therefore, we speculated that this signaling affects AC activity related to the induction of NMS.

Then, we analyzed the mechanism of the molecular interaction and genetic polymorphisms in the adrenergic receptor (α2B-AR) gene. In particular, we focused on the glutamic acid repeat polymorphism site at Glu 301--303 in the α2B-AR gene, and evaluated the phenotypes of Glu12/12, Glu12/9, and Glu9/9. By measuring the difference in the signaling time of the Gi-α subunit (GPCR), we found that the binding energy of the Gi α-subunit in Glu9 was stronger than that in Glu12 \[[@pone.0214733.ref051]\]. In addition, Small (2001) et al. reported that both Glu 9 and Glu12 repeats showed different AC activity in ovary cells of the Chinese hamster \[[@pone.0214733.ref052]\]. Thus, we primarily investigated when changes in AC activity levels markedly occur at the NMS.

Past clinical studies have investigated whether AC activity is associated with NMS in patients. We propose to test AC activity in healthy volunteers and NMS patients. Moreover, we investigate the causes of NMS syncope to develop an early diagnosis method that could be used to diagnose NMS in otherwise healthy people.

Material and methods {#sec002}
====================
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NMS patients and healthy volunteers {#sec004}
-----------------------------------

Eighteen Japanese NMS patients (11 males: 42.2 ± 21.2 yr; 7 females: 45.3 ± 21.8 yr) and 22 Japanese healthy volunteers (11 males: 33.5 ± 7.7yr; 11 females: 36.4 ± 7.2 yr) were recruited from the Tokai University School of Medicine from June 2015 to January 2018 (Tables [1](#pone.0214733.t001){ref-type="table"}, [2](#pone.0214733.t002){ref-type="table"}, [3](#pone.0214733.t003){ref-type="table"} and [4](#pone.0214733.t004){ref-type="table"}). For the HUT test, 12 healthy volunteers were selected from the 22 healthy volunteers (5 males: 32.4 ± 7.4 yr; 7 females: 38.6 ± 6.3 yr). The diagnoses of NMS patients were based on Colman, et al.\[[@pone.0214733.ref053]\] and the guidelines of the Japanese Circulation Society (<http://www.j-circ.or.jp/english/>). The type of NMS (vasodepressor type: VT, mixed type: MT, and cardioinhibitory type: CT) was diagnosed based on data obtained in the electrocardiogram, blood pressure, and pulse at the tilt test. All NMS patients fainted in the tilt test \[[@pone.0214733.ref054]\]. Organic disease was excluded.

10.1371/journal.pone.0214733.t001

###### Characteristics of the 22 healthy volunteers.

![](pone.0214733.t001){#pone.0214733.t001g}

  ---------------------------------------------------------------------------------------------------------------------
       Date         No.                                           Age   Sex      Systolic BP\   Diastolic BP\   Pulse
                                                                                 mmHg (Upper)   mmHg (Lower)    
  ---- ------------ --------------------------------------------- ----- -------- -------------- --------------- -------
  1    2015/6/22    15C015                                        23    Male     111            67              69

  2    2015/8/7     15C019                                        32    Male     118            67              65

  3    2015/9/17    15C021                                        32    Male     105            56              57

  4    2016/4/19    15C032                                        40    Male     120            79              85

  5    2016/9/29    15C041[\*](#t001fn001){ref-type="table-fn"}   43    Male     114            75              63

  6    2016/12/1    15C045                                        48    Male     117            83              82

  7    2016/12/16   15C046[\*](#t001fn001){ref-type="table-fn"}   28    Male     117            76              66

  8    2017/1/13    15C047[\*](#t001fn001){ref-type="table-fn"}   25    Male     111            59              74

  9    2016/8/26    15C040[\*](#t001fn001){ref-type="table-fn"}   29    Male     114            68              52

  10   2015/12/11   15C027                                        31    Male     109            70              83

  11   2018/1/19    15C053[\*](#t001fn001){ref-type="table-fn"}   37    Male     116            83              67

  12   2015/6/5     15C011                                        30    Female   99             67              65

  13   2015/6/5     15C012                                        28    Female   96             58              65

  14   2015/9/17    15C022[\*](#t001fn001){ref-type="table-fn"}   39    Female   96             64              71

  15   2016/2/29    15C031                                        44    Female   116            79              68

  16   2016/6/9     15C034                                        28    Female   81             55              67

  17   2016/6/24    15C036[\*](#t001fn001){ref-type="table-fn"}   47    Female   106            71              64

  18   2016/6/30    15C037[\*](#t001fn001){ref-type="table-fn"}   42    Female   108            64              71

  19   2016/7/7     15C038[\*](#t001fn001){ref-type="table-fn"}   42    Female   91             48              54

  20   2016/12/1    15C044[\*](#t001fn001){ref-type="table-fn"}   37    Female   119            76              72

  21   2017/3/10    15C048[\*](#t001fn001){ref-type="table-fn"}   36    Female   109            67              87

  22   2017/8/4     15C051[\*](#t001fn001){ref-type="table-fn"}   27    Female   93             60              78
  ---------------------------------------------------------------------------------------------------------------------

\* Implemented the HUT test as the healthy volunteers.

10.1371/journal.pone.0214733.t002

###### Average and SD of the 22 healthy volunteers.

![](pone.0214733.t002){#pone.0214733.t002g}

  -----------------------------------------------------------------------
  \                        Age     Systolic BP\   Diastolic BP\   Pulse
                                   mmHg (Upper)   mmHg (Lower)    
  ------------------------ ------- -------------- --------------- -------
  Male (Average)           33.45   113.82         71.18           69.36

  SD: standard deviation   7.74    4.45           8.96            10.69

  Female (Average)         36.36   101.27         64.45           69.27

  SD: standard deviation   7.15    11.42          9.07            8.42
  -----------------------------------------------------------------------

10.1371/journal.pone.0214733.t003

###### Characteristics of the 18 NMS patients.

![](pone.0214733.t003){#pone.0214733.t003g}

  --------------------------------------------------------------------------------------------------------
       Date         No.      NMS Type                Age   Sex      Systolic BP\   Diastolic BP\   Pulse
                                                                    mmHg (Upper)   mmHg (Lower)    
  ---- ------------ -------- ----------------------- ----- -------- -------------- --------------- -------
  1    2016/3/22    15S006   Cardioinhibitory type   20    Male     102            55              56

  2    2016/9/15    15S014   Mixed type              23    Male     119            64              63

  3    2017/1/31    15S018   Vasodepressor type      55    Male     108            75              44

  4    2017/4/4     15S022   Vasodepressor type      19    Male     127            69              68

  5    2017/4/12    15S023   Mixed type              58    Male     130            85              73

  6    2017/4/25    15S025   Vasodepressor type      67    Male     129            81              66

  7    2017/7/13    15S027   Vasodepressor type      42    Male     115            80              55

  8    2017/9/14    15S028   Vasodepressor type      21    Male     114            66              77

  9    2017/12/21   15S030   Vasodepressor type      68    Male     127            76              52

  10   2018/1/16    15S033   Vasodepressor type      67    Male     90             58              56

  11   2018/3/13    15S038   Vasodepressor type      24    Male     108            71              56

  12   2016/5/17    15S010   Vasodepressor type      70    Female   116            79              47

  13   2016/7/26    15S011   Vasodepressor type      59    Female   111            73              48

  14   2016/8/2     15S012   Mixed type              47    Female   110            69              69

  15   2016/8/9     15S013   Mixed type              27    Female   94             55              64

  16   2017/2/21    15S020   Vasodepressor type      20    Female   142            60              95

  17   2018/7/31    15S039   Mixed type              70    Female   113            75              54

  18   2018/9/18    15S040   Mixed type              24    Female   99             65              51
  --------------------------------------------------------------------------------------------------------

10.1371/journal.pone.0214733.t004

###### Average and SD of the 18 NMS patients.

![](pone.0214733.t004){#pone.0214733.t004g}

  -----------------------------------------------------------------------
  \                        Age     Systolic BP\   Diastolic BP\   Pulse
                                   mmHg (Upper)   mmHg (Lower)    
  ------------------------ ------- -------------- --------------- -------
  Male (Average)           42.18   115.36         70.91           60.55

  SD: standard deviation   21.19   12.71          9.60            9.78

  Female (Average)         45.29   112.14         68.00           61.14

  SD: standard deviation   21.75   15.36          8.54            17.04
  -----------------------------------------------------------------------

HUT test and blood collection {#sec005}
-----------------------------

All the study patients were admitted to the hospital overnight. Patients, not sedated and fasting, underwent the HUT table test between 9:00 am and 11:00 am on a tilt table set to 70°, having rested in the supine position for 15--20 min prior to recording rest time measurements. Healthy volunteers also underwent HUT testing while fasting ([Fig 1](#pone.0214733.g001){ref-type="fig"}). The lights and air conditioning were turned off for the duration of the test. Blood was collected from subjects lying on the back for the resting blood draw and we collected 8 mL of blood four times during the HUT test: at the rest time, at 70°, after 10 min, and after 20 min. After removing approximately 1 mL of blood, we switched syringes and drew another 8 mL. To avoid a false positive response, no pharmacological provocation was used and none of the patients had ingested caffeine or medication the day before the test. A positive outcome was defined as the development of syncope or presyncope in association with significant arterial hypotension. We recorded blood pressure, heart rate, and electrocardiogram readings during the HUT testing ([Fig 1](#pone.0214733.g001){ref-type="fig"}, Tables [1](#pone.0214733.t001){ref-type="table"}, [2](#pone.0214733.t002){ref-type="table"}, [3](#pone.0214733.t003){ref-type="table"} and [4](#pone.0214733.t004){ref-type="table"}).

![The head-up tilt (HUT) table and points of blood draw.](pone.0214733.g001){#pone.0214733.g001}

Comparative analysis of AC activity with changing timing {#sec006}
--------------------------------------------------------

We measured changes of the AC activity at rest in three healthy volunteers (C11, C38, C41) during different seasons. Volunteer C38 was tested on August 17^th^, 2015 and on July 7^th^, 2016. Volunteer C11was tested on June 5^th^, and after five months on November 9^th^, 2015. Volunteer C41 was tested on July15^th^, then two months later on September 9^th^, 2016. Moreover, C41 did the HUT test on July 15^th^ and on September 29^th^, 2016.

Measurement of AC activity and preparation of lymphocytes {#sec007}
---------------------------------------------------------

In order to investigate the AC activity amount, we conducted the following experimental method. We isolated the lymphocyte layer from the blood by centrifuge using BD Vacutainer Blood Collection Tubes (New Jersey, USA). Next, we washed the cells with induction Buffer (RPMI 1640, Thermo Fisher Scientific, Inc., Waltham, MA, USA) in a medium to separate platelets and isolate the lymphocytes. Test reagent was added to the lymphocytes (10 μM for 10,000 cells, respectively) and for a reaction time of 30 min at room temperature. Then, we measured the amount of cyclic adenosine monophosphate (cAMP) in accordance with the Promega cAMP-Glo Assay protocol (GloMax-Multi Detection System, [Wisconsin](https://en.wikipedia.org/wiki/Fitchburg,_Wisconsin), [USA](https://en.wikipedia.org/wiki/United_States)). Amounts of cAMP were confirmed in the standard curve ([Fig 2](#pone.0214733.g002){ref-type="fig"} and [S1 Table](#pone.0214733.s001){ref-type="supplementary-material"}). AC activities were measured in the presence of induction Buffer and /or test reagents (basal) and 100 uM FK. In our study, a concentration of 100 uM FK was reached as a plateau. The results of isoproterenol (IP) and adrenaline (AD) activity levels are expressed as percentages of forskolin (FK)-stimulated activity \[[@pone.0214733.ref052], [@pone.0214733.ref055]\].

![Standard and forskolin curves of cAMP concentrations.\
A standard curve of the cAMP concentrations.](pone.0214733.g002){#pone.0214733.g002}

Adjustment of reagent concentrations for assays (adrenaline, isoproterenol, forskolin) {#sec008}
--------------------------------------------------------------------------------------

AD is a nonselective agonist of all adrenergic receptors, including the major subtypes α and β \[[@pone.0214733.ref029], [@pone.0214733.ref033]--[@pone.0214733.ref035]\]. IP activates AC for the production of the adrenergic subtype β receptor, which promotes the binding of AC to G proteins to generate cAMP \[[@pone.0214733.ref034], [@pone.0214733.ref056]--[@pone.0214733.ref058]\]. FK activates AC in the production of cAMP \[[@pone.0214733.ref059]--[@pone.0214733.ref062]\]. Therefore, before measuring AC activity, we verified AD and IP concentrations added to lymphocytes. AD was reduced by 1 mM concentration for each 1/10 at the following concentrations: 1 nM, 10 nM, 100 nM, 1 μM, 10 μM, 100 μM, and 1 mM. IP was decreased by 5 mM for each 1/10 at the following concentrations: 5 nM, 50 nM, 500 nM, 5 μM, 50 μM, 500 μM, and 5 mM. FK was reduced by 100 μM for each 1/5 at the following concentrations: 100 uM, 20 uM, 4 uM, 800 nM, 160 nM, and 32 nM ([Fig 3A and 3B](#pone.0214733.g003){ref-type="fig"}).

![**3A and 3B. Adenylate cyclase activity levels of the 40 subjects.** A: Adrenaline was reduced by 1 mM concentration for each 1/10 at the following concentrations: 1 nM, 10 nM, 100 nM, 1 μM, 10 μM, 100 μM, and 1 mM. The circles suggested 40 total subjects ([S2 Table](#pone.0214733.s002){ref-type="supplementary-material"}). B: Isoproterenol was decreased by 5 mM for each 1/10 at the following concentrations: 5 nM, 50 nM, 500 nM, 5 μM, 50 μM, 500 μM, and 5 mM. The circles suggested 40 total subjects. Analysis of AC activity in 18 NMS subjects (Red circle) and 22 healthy volunteers (Blue circle) at rest by AD and IP ([S2 Table](#pone.0214733.s002){ref-type="supplementary-material"}). This analysis excluded one CT NMS patient.](pone.0214733.g003){#pone.0214733.g003}

Statistical analysis of AC activities {#sec009}
-------------------------------------

Data are summarized as the mean ± SD. Comparisons were made using *t*-tests as appropriate. Our analysis was performed using Microsoft Office Excel 2019 (ver. 16.10.11029.20045). Statistical analysis was performed using the Excel *t*-test and mean ± standard deviation (SD) program to confirm significant differences. Values of *p* \< 0.05 were considered significant. Excel was also used for analyzing the ratio of AC activity amount.

Results {#sec010}
=======

Measurement and analysis of AC activity in healthy volunteers and NMS patients at rest {#sec011}
--------------------------------------------------------------------------------------

We confirmed individual subjects from our results of AC activity with AD and IP ([Fig 3A and 3B](#pone.0214733.g003){ref-type="fig"}). Consequently, values between individuals were easily distinguished and observed at the following three concentrations: 1 μM, 10 μM, and 100 μM for AD ([Fig 4A](#pone.0214733.g004){ref-type="fig"}) and 500 nM, 5 μM, and 50 μM for IP ([Fig 4B](#pone.0214733.g004){ref-type="fig"}). In the 22 healthy volunteers, the average for AD was 0.54 ± 0.12 for 100 μM, 0.35 ± 0.15 for 10 μM, and 0.19 ± 0.10 for 1 μM; the average for IP was 0.44 ± 0.14 for 50 μM, 0.36 ± 0.15 for 5 μM, and 0.25 ± 0.11 for 500 nM. In the 18 NMS patients, the average for AD was 0.59 ± 0.12 for 100 μM, 0.39 ± 0.17 for 10 μM, and 0.19 ± 0.13 for 1 μM; the average for IP was 0.47 ± 0.17 for 50 μM, 0.38 ± 0.18 for 5 μM, and 0.26 ± 0.15 for 500 nM. The AC activity in NMS patients was higher than that in healthy volunteers at the three concentrations tested here. However, AD and IP were not significant in three concentrations between NMS patients and healthy volunteers (AD; 0.54 ± 0.12 for 100 μM, 0.35 ± 0.15 for 10 μM and 0.19 ± 0.10 for 1 μM, IP; 0.44 ± 0.14 for 50 μM, 0.36 ± 0.15 for 5 μM and 0.25 ± 0.11 for 500 nM) ([S2 Table](#pone.0214733.s002){ref-type="supplementary-material"}). We were then able to determine the standard value of AC activity in the healthy volunteers and the NMS subjects.

![Adenylate cyclase activity in 18 NMS patients and 22 healthy volunteers at rest.\
A and B are shown for the three concentrations (Adrenaline and Isoproterenol, respectively) of AC activity in healthy volunteers and NMS patients at rest. The AC activity of NMS patients was higher than that of healthy volunteers (AD; 0.54 ± 0.12 for 100 μM, 0.35 ± 0.15 for 10 μM and 0.19 ± 0.10 for 1 μM, IP; 0.44 ± 0.14 for 50 μM, 0.36 ± 0.15 for 5 μM and 0.25 ± 0.11 for 500 nM) at the three concentrations ([S2 Table](#pone.0214733.s002){ref-type="supplementary-material"}). (A) AD concentrations:100 μM, 10 μM, 1 μM (B) IP concentrations: 50 μM, 5 μM, 500 nM.](pone.0214733.g004){#pone.0214733.g004}

Adenylate cyclase activity in NMS patients at rest {#sec012}
--------------------------------------------------

NMS patients were divided into two groups at rest: VT and MT group ([Fig 5A and 5B](#pone.0214733.g005){ref-type="fig"}). The VT group had higher AC activity level, while the MT group had lower AC activity levels, compared to the average AC activity level in the healthy volunteer group ([S2 Table](#pone.0214733.s002){ref-type="supplementary-material"}). The higher group (A) were suggested as the VT of NMS, and the lower group (B) was mainly the MT of NMS. Next, we performed t-tests among the VT group (n = 11) of NMS patients and healthy volunteers (n = 22). From our results, the VT group had significantly higher AC activity with AD; 0.65 ± 0.11 for 100 μM: *p* = 0.005 and 0.47 ± 0.12 for 10 μM: *p* = 0.03 ([S3 Table](#pone.0214733.s003){ref-type="supplementary-material"}). IP showed significantly higher AC activity in the VT group than in the healthy volunteers at *p* = 0.02 with 0.56 ± 0.15 for 50 μM concentrations ([Fig 6A and 6B](#pone.0214733.g006){ref-type="fig"}). When the MT group (n = 6) was compared to healthy volunteers, AC activity was significantly higher in the healthy volunteers than in the NMS patients at AD concentrations of 0.25 ± 0.05 for 10 μM (p = 0.02) and AD concentrations of 0.11 ± 0.05 for 1 μM (p = 0.04). At the three IP concentrations at a 0.31 ± 0.08 for 50 μM (*p* = 0.004), 0.24 ± 0.07 for 5 μM (*p* = 0.005) and 0.17 ± 0.03 for 500 nM (*p* = 0.004) showed significantly lower AC activity in the MT group than in the healthy volunteers ([Fig 6C and 6D](#pone.0214733.g006){ref-type="fig"} and [S4 Table](#pone.0214733.s004){ref-type="supplementary-material"}). At rest time, VT tended to be higher than the average of healthy volunteers, and MT tended to be lower than the average of healthy volunteers.

![Adenylate cyclase activity in 17 NMS patients at rest.\
A and B represent the AC activities in 11 vasodepressor type (VT: gray points) and in 6 mixed type (MT: black points) at rest. The data indicated two groups (VT and MT) as border line on average of healthy volunteers (dotted black line) in NMS patients. In particular, this was confirmed at the 10 μM of AD and 5 μM of the IP. The two concentrations have a large variance of standard deviation. Therefore, we analyzed and focused on the three concentrations from the AD and IP data. Error bars show mean ± standard deviation ([S2 Table](#pone.0214733.s002){ref-type="supplementary-material"}). CT is excluded from [Fig 4C and 4D](#pone.0214733.g004){ref-type="fig"} because it has one patient. (A) AD concentrations:100 μM, 10 μM, 1 μM (B) IP concentrations: 50 μM, 5 μM, 500 nM.](pone.0214733.g005){#pone.0214733.g005}

![Analysis of AC activities in NMS subjects (VT, MT) and 22 healthy volunteers at rest.\
This figure shows the *t*-test (*p* \< 0.05) among the VT (n = 11), MT (n = 6) of NMS patients and healthy volunteers (n = 22). AD at concentrations 100 μM and 10 μM, IP at 50 μM. Error bars show mean ± standard deviation ([S3 Table](#pone.0214733.s003){ref-type="supplementary-material"} and [S4 Table](#pone.0214733.s004){ref-type="supplementary-material"}). (A) AD concentration 100 μM (B and D) IP concentration 50 μM (C) AD concentration 10 μM.](pone.0214733.g006){#pone.0214733.g006}

Measurement and analysis of AC activity between NMS patients and healthy volunteers during the HUT test {#sec013}
-------------------------------------------------------------------------------------------------------

The HUT test was analyzed according to the two different types (VT and MT) of NMS. The four points of the measurement during the HUT test showed that in the VT group (n = 11), the activity of AC with AD and IP was significantly higher than in the healthy volunteers (n = 12). The following results were observed: with 100 μM of AD, base: p = 0.009, at 70°: p = 0.01, after 10 minutes: p = 0.001, and after 20 minutes: p = 0.01; with 50 μM of IP, base: p = 0.01, at 70°: p = 0.02, after 10 minutes: p = 0.005, and after 20 minutes: p = 0.005. Significant differences were found at the other two concentrations. In the MT group, although the AC activity with AD (1 μM: p = 0.04) and IP (500 nM: p = 0.04) was slightly lower in healthy volunteers during the HUT test (rest time), there was either no change or a decrease in AC activity ([Fig 7A, 7B, 7C and 7D](#pone.0214733.g007){ref-type="fig"}). However, 10 minutes after the tilt table set to 70°, AC activities had risen sharply, although this was not significant. In the VT and MT groups, AC activity markedly increased 10 minutes after head-up tilt 70° stress, which is thought to be due to presyncope or syncope.

![Analysis of AC activities in NMS subjects (VT, MT) and 22 healthy volunteers during the HUT test.\
This figure shows the analyzed *t*-test (*p* \< 0.05) among the VT (n = 11), MT (n = 6) of NMS patients and healthy volunteers (n = 12). AD at concentrations 100 μM and 1 μM, IP at 50 μM. Error bars show mean ± standard deviation ([S5 Table](#pone.0214733.s005){ref-type="supplementary-material"} and [S6 Table](#pone.0214733.s006){ref-type="supplementary-material"}). \* Some patients were in poor condition around 10 minutes from the tilt table set to 70°at the HUT test. (A) AD concentrations (100 μM) (B) IP concentrations (50 μM) (C) AD concentrations (1μM) (D) IP concentrations (500 nM).](pone.0214733.g007){#pone.0214733.g007}

AC activities in the different seasons from three volunteers at rest and during the HUT test {#sec014}
--------------------------------------------------------------------------------------------

In the three healthy volunteers (C11, C38, C41), there was no change in AC activity between different time points (separated by 11 months, five months, or two months) ([Fig 8A, 8B and 8C](#pone.0214733.g008){ref-type="fig"}). Moreover, the C41 healthy volunteer did not show a large change during the HUT tests performed at different times. From our results, we do not know exactly if the AC activity values have been decided to each person. However, irrespective of the season, AC activity was similar in each of the three volunteers and the change was minimal in C41 for the two HUT tests ([Fig 9A, 9B, 9C and 9D](#pone.0214733.g009){ref-type="fig"}).

![The AC activities during the different seasons from three volunteers at rest.\
(A) The AC activity in the C38 volunteer was measured on Aug. 17^th^, 2015 and Jul. 7^th^, 2016. (B) The AC activity in the C11 volunteer was measured on Jun. 5^th^, 2015 and Nov. 9^th^, 2015. (C) The AC activity in the C41 volunteer was measured on Jul. 15^th^, 2016 and Sep. 29^th^, 2016. Upper: Adrenaline Lower: Isoproterenol ([S7 Table](#pone.0214733.s007){ref-type="supplementary-material"}).](pone.0214733.g008){#pone.0214733.g008}

![**The AC activities in two different seasons from the C41 volunteer during the HUT test (A: Base, B: 70°, C: 10 min, D: 20 min) (July. 15**^**th**^**, 2016 and Sep. 29**^**th**^**, 2016).** Upper: Adrenaline Lower: Isoproterenol ([S8 Table](#pone.0214733.s008){ref-type="supplementary-material"}).](pone.0214733.g009){#pone.0214733.g009}

Discussion {#sec015}
==========

To clarify the mechanism of NMS, we focused on the AC activity level at the time of NMS. From our results, we were able to determine the standard value of AC activity when AD and IP were added to lymphocytes. Our study showed a significant difference in AC activity between NMS patients and healthy volunteers at rest and during the HUT test. Interestingly, the NMS types (VT or MT) could be distinguished based on AC activity level by how high or low the activities is. The AC activity (with AD 100 μM and IP 50 μM) is significantly higher in the VT patients than in the healthy volunteers at rest. In addition, the VT was significantly higher than healthy volunteers at the four points of the HUT test. AC activity (AD 10 μM and IP 50 μM) is significantly lower in the MT patients than in the healthy volunteers at rest. We think that the action of the Gi-α (inhibit) or Gs-α (stimulate) subunits are relative to the AC activities occur at the onset of NMS patients. The stimulatory Gs protein activates AC to increase intracellular cAMP. Gi protein inhibit the activation of AC. Therefore, our result suggests that AC activity of VT patients is higher because it is influence by Gi-α subunit and Gs-α subunit. VT patients seems to have relatively stronger action of the Gs-α subunit. In MT patients, the action of Gs-α subunit is weaker, and it is also considered that the AC activity level is lower do to the action of Gi-α subunit. In healthy volunteers, the balance of action between Gi-α and Gs-α subunits has been maintained.

Also, both VT and MT groups, AC activity markedly increased 10 minutes after head-up tilt 70° stress, which is thought to be due to presyncope or syncope. Therefore, we found that it is possible for this data to be used as a diagnosis of NMS patients by AC activity levels. From our results, it became clear that AC activity is strongly related to the appearance of NMS. NMS diagnosis can be determined by examining AC activity levels from blood tests at rest time, without the requirement of performing the HUT test.

In the three healthy volunteers, there was no change in AC activity between HUT tests or between different time points (separated by 11 months, five months, or two months). If the AC activity level can be clarified, and which points at the growth process are determined, it is possible to diagnose a very early risk of NMS patients in the future by conducting AC activity tests at the earliest possible time. Even in environments where it is difficult to diagnose VT and MT, AC activity can become a useful diagnosis tool of NMS.

Based on the different AC activity levels in this study, regarding coping with NMS, it may be necessary to adjust caffeine intake in addition to tilt stretching. Caffeine acts to increase cAMP (AC activity) concentration in cells \[[@pone.0214733.ref063]--[@pone.0214733.ref067]\]. From our results, patients who have higher AC activity levels than healthy volunteers are at a higher risk of NMS if they ingest caffeine. Conversely, patients with low AC activity may benefit from ingesting food containing caffeine. Because there is no treatment for NMS, suppressing the onset of NMS by adjusting the intake of tea or coffee seems a very easy preventive method.

The final goal of our research is to identify an early diagnosis of NMS and potentially prevent fainting and their associated injuries. Studies examining AC activity in a larger sample size are necessary to confirm the reliability of our findings. Furthermore, in our next report we are discussing the cause of NMS from the multilateral relationship of the glutamic acid repeat polymorphism site at Glu 301--303 in the α2B-AR gene, and evaluated the phenotypes or gene frequency of Glu12/12, Glu12/9, and Glu9/9.

We believe that AC activity tests could be implemented in job applicants for positions involving low gravity stress while operating ultra-high-speed aircraft, linear motor cars, space stations, as well as in long distance truck, bus, and train drivers or an aircraft pilot. In addition, the research in our study may be useful in creating an improved standard of medical management for stress during times of unexpected, large scale disasters in Japan's future. We believe in the possibility of developing therapeutic drugs for NMS diseases.

Conclusions {#sec016}
===========

Our study showed a significant difference in AC activities between NMS patients and healthy volunteers at rest and during the HUT test. In addition, we found different patterns among the two NMS types (VT or MT) based on AC activity level. Especially, by examining AC activity level from the blood at rest, it is possible to diagnose NMS patients. Based on our data, we might be able to find people with a high risk of developing NMS from healthy people.

Supporting information {#sec017}
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###### An example raw data of healthy volunteer (C48).

(PDF)

###### 

Click here for additional data file.

###### The raw data of adenylate cyclase activities from 22 healthy volunteers and 18 NMS patients at rest time by adrenaline (AD) and isoproterenol (IP).

(PDF)

###### 

Click here for additional data file.

###### The raw data of adenylate cyclase activities from 22 healthy volunteers and 11 VT patients at rest time by adrenaline (AD) and isoproterenol (IP).

(PDF)

###### 

Click here for additional data file.

###### The raw data of adenylate cyclase activities from 22 healthy volunteers and 6 MT patients at rest time by adrenaline (AD) and isoproterenol (IP).

(PDF)

###### 

Click here for additional data file.

###### The raw data of adenylate cyclase activities from 12 healthy volunteers and 11 VT patients at HUT test by adrenaline (AD) and isoproterenol (IP).

(PDF)

###### 

Click here for additional data file.

###### The raw data of adenylate cyclase activities from 12 healthy volunteers and 6 MT patients at HUT test by adrenaline (AD) and isoproterenol (IP).

(PDF)

###### 

Click here for additional data file.

###### The raw data of adenylate cyclase activities in the different seasons from three volunteers by adrenaline (AD) and isoproterenol (IP).

Upper: Adrenaline

Lower: Isoproterenol.

(PDF)

###### 

Click here for additional data file.

###### The raw data of adenylate cyclase activities in the different seasons from C41 volunteer by adrenaline (AD) and isoproterenol (IP).

The AC activities in the different seasons from the healthy volunteer during the HUT test. HUT was tested in two different seasons on the 15^th^ of July and the 29^th^ of September.

Upper: Adrenaline

Lower: Isoproterenol.

(PDF)

###### 

Click here for additional data file.
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